Immunotherapy Plus Checkpoint Inhibition in Recruiting Colorectal Cancer Trial
A Phase III multicenter trial evaluating the combination of nivolumab and ipilimumab in patients with mismatch repair-deficient metastatic colorectal cancer is currently recruiting. Preliminary…